Regeneron Pharmaceuticals has reported past full-year 2025 results showing modest revenue and net income growth, completed a US$1.51 billion share repurchase, and highlighted upcoming long-term EYLEA ...
Source LinkRegeneron Pharmaceuticals has reported past full-year 2025 results showing modest revenue and net income growth, completed a US$1.51 billion share repurchase, and highlighted upcoming long-term EYLEA ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.